• Eli Lilly announced a significant R&D and licensing collaboration with China's Abbisko Therapeutics, potentially worth up to $1.9 billion, to develop novel therapies.
  • The company also successfully completed its acquisition of Centessa Pharmaceuticals plc, aiming to advance medicines for narcolepsy and other sleep disorders.
  • Furthermore, Eli Lilly is investing in AI-driven drug development by creating a research platform for scientists, leveraging strong cash flow from its weight-loss medications.